Similarly, HSC2–6 cells mobilized in allo-donors with motixafortide, but not plerixafor or G-CSF, expressed increased levels of JUNB and NR4A1. By contrast, gene expression profiles of the HSC1–6 and MLP populations were more homogenous within the MM cohorts, potentially reflecting the impact of recent MM-targeting induction therapies on the bone marrow niche, as well as increased age and/or a pre-existing diagnosis of MM. The gene discussed is NR4A1; the disease is Miyoshi myopathy.